GSC Biological and Pharmaceutical Sciences
eISSN: 2581-3250 CODEN (USA): GBPSC2
Cross Ref DOI: 10.30574/gscbps
Journal homepage: https://gsconlinepress.com/journals/gscbps/

(REVIEW ARTICLE)

Check for updates

Emerging trends in computational approaches for drug discovery inmolecular biology

Yakubu Magaji Yuguda [1, *, #], Israel Ebehitale Unuebho [2, #], Tejonidhi kolli [3] and Jeeva Dhanushya [4]

[1] *Federal Polytechnic, Kaltungo, Gombe State, Nigeria.*
[2] *National Biotechnology Development Agency (NABDA), Umar Musa, Yar'Adua Way, Lugbe, Nigeria.*
[3] *Bhaskar Pharmacy College, Jawaharlal Nehru Technological University, (JNTU), Hyderabad, India.*
[4] *Department of Biotechnology, Sri Venkateswara College of Engineering, Kanchipuram, Chennai, India.*
[#] *Both authors contributed equally to this manuscript.*

GSC Biological and Pharmaceutical Sciences, 2023, 24(03), 202–213

Publication history: Received on 11 July 2023; revised on 20 August 2023; accepted on 23 August 2023

Article DOI: https://doi.org/10.30574/gscbps.2023.24.3.0340

Abstract

Purpose of Research: This review paper delves into the transformative impact of computational approaches on drug discovery within molecular biology. It explores how these methods offer efficient and cost-effective solutions to identify and optimize potential drug candidates, addressing the shortcomings of traditional drug discovery methods.

Scope of the Experiments: Algorithms, machine learning, artificial intelligence, and quantum mechanics are studied. These approaches analyse large datasets, anticipate drug- target interactions, and improve drug design. Supervised and unsupervised learning techniques enable chemical space exploration, target identification, and compound classification. Bioinformatics and data mining enable target identification, drug discovery, and personalised treatment by analysing large biological databases. Quantum mechanics- based techniques reveal molecular structures, interactions, and reactions, improving drug design and optimisation.

Results and Findings: The review demonstrates that computational approaches have the potential to expedite drug discovery by leveraging machine learning, artificial intelligence, quantum mechanics, Big Data, and omics methods. These techniques enable accurate prediction of drug-target interactions and efficient exploration of chemical and biological spaces. The integration of diverse datasets enhances target identification and personalized medicine, while quantum mechanics-based insights improve drug design.

Conclusions: Despite their benefits, computational approaches face challenges such as model accuracy, efficiency, and validation. Nonetheless, this review underscores the significance of these approaches and their applications in drug discovery. By addressing challenges and embracing emerging technologies, the field can propel advancements in computational drug discovery. This progress will not only benefit patients but also advance the overall landscape of healthcare.

Keywords: Computational Approaches; Drug Design; Drug Discovery; Machine Learning; Artificial Intelligence; Quantum Mechanics

1. Introduction

Computational approaches to drug discovery have revolutionized the field of molecular biology by offering powerful tools and methodologies to accelerate the identification and development of new therapeutic agents [1]. Traditional experimental approaches have often been time- consuming, resource-intensive, and prone to high failure rates in the

* Corresponding author: Yakubu Magaji Yuguda

quest for novel drugs [2]. The emergence of computational techniques has provided an innovative and efficient alternative, allowing researchers to harness the power of computers to expedite the drug

discovery process. The significance and relevance of computational approaches in advancing drug discovery processes cannot be overstated [1, 3]. With the exponential growth of biological data and the increasing complexity of molecular interactions, computational methods offer a systematic and scalable approach to tackle the immense challenges faced by researchers [3]. These approaches enable the prediction and analysis of molecular structures, interactions, and properties with unprecedented speed and accuracy, significantly reducing the time and cost associated with traditional trial-and-error experimentation.

By exploring the latest advancements and techniques in this rapidly evolving field, we aim to shed light on the potential of computational methods to transform the landscape of drug discovery and development. From machine learning and artificial intelligence to big data analysis, molecular dynamics simulations, and quantum mechanics-based approaches, we will delve into the various computational tools and strategies employed to facilitate the identification of promising drug candidates. Ultimately, this review aims to foster a deeper appreciation of the transformative potential of computational approaches for drug discovery in molecular biology and inspire further research and innovation in this exciting field.

2. Traditional Drug Discovery Methods

Traditional drug discovery methods have long been the cornerstone of pharmaceutical research and development. These methods typically rely on a series of experimental approaches and empirical observations to identify potential drug candidates. While these techniques have led to numerous successful therapies, they suffer from inherent limitations and challenges that impede the efficient and timely discovery of new drugs. Traditional drug discovery methods encompass a range of strategies, including high-throughput screening, target-based approaches, and natural product discovery.

2.1. High-Throughput Screening

High-throughput screening (HTS) is a widely used traditional drug discovery method that involves testing large libraries of compounds against specific biological targets or assays [4]. HTS allows for the rapid screening of thousands to millions of compounds to identify potential drug leads. It involves several key steps, including compound library preparation and assay development. HTS requires a diverse and representative collection of compounds known as a compound library [5]. These libraries can consist of thousands to millions of small molecules or natural product extracts. The compounds in the library are typically selected based on their structural diversity, drug- likeness properties, and commercial availability. Compound libraries can be sourced from various vendors, synthesized in-house, or derived from natural product extracts [5]. In comparison, assay development involves designing and optimizing a robust biological or biochemical assay that allows the measurement of a specific target or activity relevant to the disease or condition of interest [4, 5]. The choice of the assay depends on the target and the intended mode of action of the drug. Assays can range from enzyme-based assays, receptor-binding assays, and cell-based assays to phenotypic assays.

During assay development, optimization of experimental conditions, such as buffer composition, temperature, and reaction time, is performed to ensure robust and reproducible results [6]. Controls and reference compounds are included to validate the assay performance and provide a baseline for comparison. Once the compound library and assay are ready, the HTS process begins. It involves steps including plate preparation, compound dispensing, the addition of test samples, incubation and measurement, and data analysis [7]. The advantages and limitations of HTS, such as its ability to generate a large number of hits but with potential issues of false positives and false negatives. The time, cost, and resources required for conducting high-throughput screening [8, 9]. Strategies to improve the efficiency and reliability of HTS, such as the use of advanced robotics, miniaturization, and automated data analysis.

2.2. Target-Based Approaches

Target-based approaches involve identifying a specific biological target, such as a protein or enzyme associated with a disease, and designing compounds to modulate its activity [10]. While this approach allows for rational drug design, it heavily relies on the detailed knowledge of the target and its associated pathways, which may not always be available or fully understood. Moreover, the experimental determination of the three-dimensional structure of the target protein can be challenging, further complicating the design of targeted drugs [11]. Challenges in target identification include the need for comprehensive knowledge of disease pathways and protein structures.

2.3. Natural Product Discovery

Natural product discovery involves the exploration of compounds derived from natural sources, such as plants, marine organisms, and microorganisms [12]. Natural products have played a crucial role in drug discovery throughout history [13]. Many important drugs, including antibiotics, anticancer agents, and cardiovascular medications, have been derived from natural sources [12, 13].

Traditional medicine systems worldwide have long utilized natural products for their therapeutic properties. The study of natural products has led to the discovery of bioactive compounds with diverse chemical structures and pharmacological activities [14]. The process of natural product discovery involves several steps for isolating, identifying, and characterizing bioactive compounds, including collection from diverse environments, including forests, oceans, and soil, extraction using solvent extraction, maceration, and fermentation, isolation using chromatography, including column chromatography, high- performance liquid chromatography (HPLC), and preparative thin-layer chromatography (TLC), and structure elucidation using nuclear magnetic resonance (NMR), mass spectrometry (MS), and X-ray crystallography.

Natural product discovery faces several challenges, including limited availability, scalability, and modification of natural product structures [15]. To overcome challenges in natural product discovery, researchers have adopted various approaches, including bioinformatics tools for genome mining and metagenomics [16]. Bioinformatics tools analyze genomic data from organisms to predict and identify potential biosynthetic gene clusters involved in natural product synthesis. This approach facilitates the discovery of novel natural products by targeting specific biosynthetic pathways. In contrast, metagenomics involves the direct analysis of genetic material from environmental samples. It enables the exploration of microbial communities and their potential to produce unique and diverse natural products.

2.4. Limitations of Traditional Drug Discovery Methods:

Traditional drug discovery methods, while valuable, face several limitations that impede the efficient and successful development of new drugs [17]. Traditional drug discovery processes often suffer from high failure rates and attrition. Many potential drug candidates fail to progress beyond the early stages of development due to issues such as lack of efficacy, poor pharmacokinetics, or unexpected toxicity [18]. This attrition leads to significant time and resource wastage. The drug discovery process can be lengthy and costly, from hit-to-lead optimization to clinical development [19]. It typically takes several years and requires substantial financial investments to bring a drug candidate from the laboratory to the market. The extensive testing, regulatory requirements, and clinical trials involved contribute to these prolonged timelines and high costs [19]. To develop effective drugs, a thorough understanding of the underlying disease biology and the identification of suitable drug targets are crucial. However, in many cases, the mechanisms and pathways associated with diseases are not fully understood, making target identification challenging [20]. This lack of comprehensive knowledge can hinder the rational design and development of drugs targeting specific diseases. Traditional drug discovery methods often rely on empirical observations and trial- and-error approaches. This means that researchers explore a large number of compounds or test various modifications without a comprehensive understanding of their mechanisms of action. This trial-and-error process can be time-consuming, resource-intensive, and may not always yield optimal results. The discovery of new chemical scaffolds with unique properties is essential for developing innovative drugs [21]. However, traditional methods often rely on existing chemical libraries, leading to a scarcity of novel compounds. This limited chemical diversity can restrict the identification of drugs with novel mechanisms of action or desired pharmacological properties. Furthermore, the risk of developing drugs with limited efficacy or safety concerns remains a challenge.

Addressing these limitations and overcoming the hurdles in traditional drug discovery methods require the integration of computational approaches, advanced technologies, and innovative strategies. The emerging trends in computational approaches for drug discovery offer promising solutions to expedite the process, improve success rates, and optimize the development of safe and effective drugs.

3. Machine Learning and Artificial Intelligence in Drug Discovery

Machine learning (ML) and artificial intelligence (AI) have emerged as powerful drug discovery tools, revolutionizing how researchers identify and develop potential drug candidates. ML and AI algorithms can analyze large, complex datasets, including biological, chemical, and clinical data, to extract meaningful patterns and correlations [22-24]. These techniques enable the prediction of drug-target interactions, compound properties, toxicity, and efficacy. ML and AI algorithms can efficiently screen large compound libraries and databases to identify potential drug candidates [25]. By leveraging historical data, these methods enable the repurposing of existing drugs for new indications, saving time and resources. ML and AI techniques can generate novel drug-like compounds by employing generative models and

reinforcement learning [26]. These methods explore chemical space and propose new molecular structures with desired properties. ML and AI algorithms can optimize lead compounds by performing virtual screening and molecular docking simulations [27]. These techniques help prioritize compounds with high binding affinity, selectivity, and favourable pharmacokinetic properties. ML and AI models can predict the potential toxicity and safety risks of compounds by analyzing chemical structures and biological data [28]. These methods aid in the early identification and elimination of potentially harmful compounds. ML and AI algorithms can optimize the clinical trial design by analyzing patient data, genetic profiles, and historical trial outcomes [29]. These techniques help improve patient selection, treatment response prediction, and trial efficiency. ML and AI methods can predict optimal drug combinations by analyzing drug-target interactions and molecular pathways [30, 31]. These approaches facilitate the identification of synergistic drug pairs for enhanced therapeutic efficacy.

3.1. Data Analysis and Predictive Modeling

ML and AI algorithms excel at analyzing large and complex datasets, making them invaluable for data-driven drug discovery [24, 25]. These techniques can extract patterns, relationships, and predictive models from diverse sources of data, including genomics, proteomics, chemical structures, and clinical data. By integrating and mining these datasets, ML and AI can assist in predicting drug-target interactions, compound property prediction, and pharmacokinetics and pharmacodynamics modelling [27, 28]. ML models can predict the likelihood and strength of interactions between drug molecules and specific target proteins, aiding in target identification and lead optimization. ML algorithms can predict various compound properties, such as solubility, permeability, bioavailability, and toxicity, helping researchers prioritize compounds with desirable characteristics [28]. ML and AI can simulate and predict drug behaviour in the body, such as absorption, distribution, metabolism, excretion, and efficacy, aiding in dosage optimization and understanding drug mechanisms.

3.2. Virtual Screening and Drug Repurposing

ML and AI algorithms enable virtual screening, which involves computationally screening large compound libraries or databases to identify potential drug candidates [32]. These methods can accelerate hit identification and facilitate drug repurposing [27]. ML models can prioritize compounds with a higher probability of binding to a specific target, reducing the time and cost required for experimental screening [27, 32]. ML and AI techniques leverage existing knowledge to identify new therapeutic uses for approved drugs by predicting their efficacy against different diseases, potentially saving years of development time.

3.3. De Novo Drug Design

ML and AI have enabled the exploration of chemical space for the design of novel drug-like compounds [33, 34]. These techniques employ generative models, reinforcement learning, and deep learning to propose and optimize new molecular structures with desired properties, including generative models and reinforcement learning. ML algorithms can generate novel molecules with specific structural features and properties, aiding in the design of lead compounds [34]. AI techniques can optimize drug- like properties by iteratively learning from chemical rules and optimizing molecular structures.

3.4. Predictive Toxicity and Safety Assessment

ML and AI models are crucial for predicting the potential toxicity and safety risks of compounds [28, 35]. These methods can predict toxicity profiles and virtual ADME-Tox profiling by analyzing chemical structures, biological data, and adverse event databases [28, 36]. ML algorithms can assess the potential toxicity of compounds, allowing researchers to eliminate or modify compounds with undesirable safety profiles. ML models can predict the absorption, distribution, metabolism, excretion, and toxicity (ADME-Tox) properties of compounds, helping prioritize compounds with favourable pharmacokinetics and reducing the likelihood of adverse effects [36, 28].

3.5. Clinical Trial Optimization

ML and AI algorithms are instrumental in optimizing clinical trial design, patient selection, and treatment response prediction [37]. By analyzing patient data, genetic profiles, and historical trial outcomes, these techniques can improve patient selection and optimize trial design. ML models can identify patient characteristics or biomarkers that influence treatment response, aiding in patient stratification and personalized medicine [38]. AI algorithms can optimize trial design parameters, such as sample size, treatment arms, and trial duration, to enhance efficiency and reduce costs.

3.6. Drug Combination and Synergy Prediction

ML and AI methods play a crucial role in predicting optimal drug combinations [30]. By analyzing drug-target interactions, molecular pathways, and genomic data, these approaches can Identify Synergistic Combinations and Design Combination Therapies. ML algorithms can predict drug combinations that exhibit synergistic effects, enhancing therapeutic efficacy and minimizing resistance [30, 39]. AI techniques can optimize the dosing schedules and ratios of drugs in combination therapies to maximize their effectiveness.

The application of ML and AI in drug discovery holds immense potential for streamlining the process, reducing costs, and increasing success rates. These technologies enable researchers to make data-driven decisions, uncover novel insights, and accelerate the development of safe and effective therapies, ultimately benefiting patients and improving global healthcare.

3.7. Supervised and Unsupervised Learning

Supervised learning algorithms are used in drug discovery for predictive modelling, QSAR modelling, virtual screening, and other tasks where labelled data is available to train models and make predictions based on input features [40, 41]. In contrast, unsupervised learning algorithms are employed in drug discovery for clustering compounds, dimensionality reduction, anomaly detection, and data preprocessing tasks [42]. They help identify patterns, group similar compounds, reduce data complexity, and detect outliers in unlabeled datasets. Sometimes, a combination of supervised and unsupervised learning methods is used in drug discovery [43]. Unsupervised learning techniques can be used for initial data exploration and feature extraction, followed by supervised learning to build predictive models on transformed data. The choice between supervised and unsupervised learning depends on the nature of the data, specific objectives, and the stage of the drug discovery process. By leveraging both types of algorithms, researchers gain valuable insights, make accurate predictions, and extract meaningful information from the vast amount of data encountered in drug discovery.

3.8. Deep learning and neural networks in predicting drug-target interactions:

Deep learning and neural networks play a crucial role in predicting drug-target interactions [44]. They excel at capturing non-linear relationships between drug features and target characteristics, enabling more accurate predictions. By learning from large-scale data, deep learning models can generalize well to unseen drug-target pairs. They automatically learn meaningful representations of drug and target data, extracting hierarchical features and enhancing understanding [45]. Deep learning models integrate multi-modal data, such as chemical structures and genomic data, providing a comprehensive view of interactions [46]. Transfer learning and pre-trained models allow for efficient training with limited labelled data. Deep learning models can provide insights into the factors influencing interactions and contribute to the identification of potential drug candidates and personalized medicine.

4. Big Data and Omics Approaches

4.1. Utilization of Big Data in Drug Discovery

In recent years, the field of drug discovery has witnessed an explosion of data generated from various sources, giving rise to the era of Big Data [47]. Big Data refers to large and complex datasets that are challenging to process and analyze using traditional methods [3]. In drug discovery, Big Data encompasses a wide range of information, including chemical structures, genomic sequences, protein structures, clinical data, and more [42]. The utilization of Big Data has revolutionized the drug discovery process, enabling researchers to gain deeper insights into diseases, identify novel drug targets, optimize drug design, and accelerate the development of new therapies [3, 47].

4.2. Integration of Omics Data in Computational Approaches

Omics refers to the comprehensive study of various biological molecules and their interactions within a biological system [48]. Omics data, including genomics, proteomics, metabolomics, transcriptomics, and more, provide valuable information about the molecular characteristics, functions, and dynamics of living organisms [49, 50]. In drug discovery, the integration of omics data into computational approaches has become increasingly important. By incorporating omics data, researchers can gain a holistic understanding of disease mechanisms, identify potential drug targets, and discover novel biomarkers for diagnosis, prognosis, and personalized treatment.

4.3. Genomics

Genomics is the study of an organism's complete set of DNA, including genes and non-coding regions. Genomic data plays a significant role in drug discovery by providing insights into genetic variations, disease-associated genes, and potential drug targets [51]. Genome-wide association studies (GWAS) analyze genomic data from large populations to identify genetic variants associated with disease susceptibility or treatment response [52]. Next-generation sequencing (NGS) technologies enable rapid and cost- effective sequencing, facilitating the identification of disease-causing mutations, genetic biomarkers, and therapeutic targets [53, 54].

4.4. Proteomics

Proteomics focuses on the study of proteins, their structures, functions, and interactions within a biological system [55]. Proteomic data offers valuable information about protein expression levels, post-translational modifications, and protein-protein interactions relevant to disease processes. Mass spectrometry plays a crucial role in proteomics, enabling protein identification, quantification, and characterization [55]. By integrating proteomic data, researchers can identify potential drug targets, understand protein signalling pathways, and assess the efficacy of therapeutic interventions [56].

4.5. Metabolomics

Metabolomics involves the comprehensive study of small molecules, known as metabolites, within a biological system [57]. Metabolomic data provide insights into the metabolic pathways, biochemical changes, and metabolic profiles associated with diseases [58, 59]. Metabolic profiling allows the identification of disease-specific biomarkers and drug metabolites and the evaluation of drug efficacy and toxicity [60]. By integrating metabolomic data, researchers can gain a deeper understanding of disease mechanisms, identify therapeutic targets, and optimize drug design.

4.6. Other Omics Approaches

In addition to genomics, proteomics, and metabolomics, other omics approaches contribute to drug discovery. Transcriptomics focuses on studying gene expression levels and patterns, providing insights into disease-related gene regulation and identifying potential drug targets [61, 62]. Epigenomics investigates the modifications of DNA and histones, revealing how gene expression is regulated and contributes to drug development 63, 64]. Pharmacogenomics aims to understand how genetic variations influence drug response and guide personalized medicine approaches [65, 66].

4.7. Role of Data Mining and Bioinformatics in Analyzing Large-Scale Biological Datasets

Data mining and bioinformatics play essential roles in analyzing and extracting valuable information from large-scale biological datasets [67]. Data mining techniques, such as clustering, classification, and pattern recognition, help identify meaningful relationships, similarities, and patterns within complex datasets [68]. In drug discovery, data mining facilitates identifying drug candidates, predicting drug-target interactions, and analyzing drug safety and efficacy [69-71].

Bioinformatics encompasses a range of computational tools and techniques for analyzing biological data. Databases and repositories store vast amounts of biological information, including genomic sequences, protein structures, and drug-related data. Computational analysis tools enable sequence alignment, protein structure prediction, molecular docking, network analysis, and pathway mapping. Machine learning and statistical methods are utilized to develop predictive models, classify biological data, and extract meaningful insights from high- dimensional omics datasets. Therefore, the integration of Big Data and omics approaches in drug discovery has revolutionized the field, enabling researchers to leverage vast amounts of data for a deeper understanding of diseases, identification of drug targets, and optimization of therapeutic interventions. Data mining and bioinformatics play pivotal roles in analyzing and extracting valuable information from large-scale biological datasets, facilitating the discovery and development of novel drugs and personalized treatment strategies.

5. Quantum Mechanics-Based Approaches

Quantum mechanics-based approaches have gained significant attention in recent years as powerful tools for drug discovery [72]. These approaches involve applying the principles of quantum mechanics, a branch of physics that describes the behaviour of matter at the atomic and subatomic levels, to study and predict the properties and interactions of drug molecules and their targets. By harnessing the computational power of quantum mechanics,

researchers can gain insights into molecular structures, chemical reactions, and intermolecular forces, leading to more accurate drug design and optimization [73].

5.1. Application of quantum mechanics in drug design and optimization

Quantum mechanics-based methods find applications at various stages of the drug discovery process, offering unique insights and capabilities [74, 75]. They can be used to study the electronic structure and energy landscapes of molecules, predict molecular properties, and understand the mechanisms of molecular interactions. Some specific applications of quantum mechanics in drug design include structure determination, binding affinity prediction, and reaction mechanisms [76]. Quantum mechanics-based methods, such as density functional theory (DFT) and ab initio calculations, allow for the accurate determination of molecular structures, including bond lengths, angles, and torsional potentials [77, 78]. This information aids in understanding the three-dimensional shape of molecules and their interactions with target proteins. Quantum mechanics calculations can be used to estimate the binding affinity between drug molecules and target proteins [79]. Researchers can assess the strength of the drug-target interactions by calculating the interaction energies and studying the non-covalent interactions involved, such as hydrogen bonding, van der Waals forces, and π-π stacking. Quantum mechanics methods enable the study of reaction mechanisms, providing insights into the steps involved in chemical reactions [80, 81]. This knowledge helps understand drug metabolism, identify potential reactive intermediates, and optimize drug stability and bioavailability.

5.2. Advantages and challenges of quantum mechanics-based methods

Quantum mechanics-based approaches offer several advantages in drug discovery, including accuracy, molecular-level insights, and rational design [82, 83]. Quantum mechanics provides high accuracy in predicting molecular properties and interactions, allowing for more reliable drug design and optimization [84]. These methods provide detailed insights into the electronic structure, charge distribution, and bonding patterns of drug molecules and their targets, aiding in understanding the underlying mechanisms of drug action. Quantum mechanics-based approaches enable rational drug design by providing precise information about molecular properties and interactions, allowing for the modification and optimization of drug candidates.

However, there are challenges associated with quantum mechanics-based methods, including Computational Resources, Simplifications and Approximations, and Scalability. Quantum mechanics calculations are computationally demanding, requiring substantial computational resources and time. Handling large systems or studying dynamic processes can be particularly challenging. Some quantum mechanics methods rely on simplifications and approximations to make calculations tractable, which may introduce errors or limitations in certain cases. The scalability of quantum mechanics-based methods to larger systems and longer time scales remains a challenge, hindering their application to complex biological systems.

Despite these challenges, quantum mechanics-based approaches hold tremendous potential in drug discovery and are continuously advancing with the development of novel algorithms, computational techniques, and increased computing power. As researchers continue to explore and refine these methods, they are expected to play an increasingly significant role in designing safer and more effective drugs.

5.3. Challenges and Future Perspectives

The current challenges and limitations in computational approaches for drug discovery highlight the need for continuous improvement and advancement in the field. Despite significant progress, computational models still face limitations in accurately predicting complex biological systems and drug-target interactions. Improving the accuracy and reliability of computational models remains a challenge, especially for large-scale and dynamic systems. Validating and reproducing computational results is crucial for establishing the credibility of the models and ensuring their reliability. Developing standardized protocols and benchmarks for validation is necessary to enhance the trustworthiness of computational approaches. The success of computational approaches relies heavily on data availability and quality. Access to comprehensive and well-curated datasets, including chemical, biological, and clinical information, is essential for building robust models. Ensuring data quality, standardization, and integration across different sources remains a challenge. The increasing complexity of computational models requires substantial computing resources. Access to high-performance computing infrastructure and efficient algorithms is crucial to handle large datasets, complex simulations, and computationally intensive calculations.

In the future, several trends and advancements are expected to shape the field of computational approaches for drug discovery. Integrating diverse data types, such as genomics, proteomics, metabolomics, and clinical data, will provide a more comprehensive understanding of diseases and enable the development of personalized medicine approaches.

Further advancements in machine learning and artificial intelligence techniques will enhance the predictive power of computational models. Combined with large-scale datasets, deep learning and neural networks will facilitate more accurate predictions and accelerate drug discovery processes. The emergence of quantum computing holds promises for tackling complex problems in drug discovery that are computationally intractable for classical computers. Quantum computing may provide new insights into molecular interactions, optimization algorithms, and drug design. The integration of computational models with high-throughput experimental techniques, such as high-throughput screening and omics technologies, will enable faster and more efficient validation of computational predictions. Increased data sharing and collaboration among researchers, pharmaceutical companies, and regulatory agencies will foster the development of more robust and reliable computational models. Open data initiatives and collaborative platforms will facilitate knowledge sharing and accelerate drug discovery efforts.

While computational approaches for drug discovery have made significant progress, several challenges and limitations still need to be addressed. Improving accuracy, efficiency, and validation of computational models, along with the integration of multi-modal data and advancements in machine learning and quantum computing, will shape the future of the field. Collaborative efforts, data sharing, and standardization will further enhance the impact of computational approaches in accelerating the discovery and development of safe and effective drugs.

6. Conclusion

Computational approaches have revolutionized the field of drug discovery, offering powerful tools and methodologies to expedite the identification and optimization of novel drug candidates. Traditional drug discovery methods, while valuable, are often time-consuming, costly, and prone to high failure rates. Computational approaches have emerged as complementary, providing efficient and cost-effective solutions to overcome these challenges. Researchers can now analyze vast amounts of data, predict drug-target interactions, optimize drug design, and streamline the drug discovery process by leveraging computational algorithms, machine learning, artificial intelligence, and quantum mechanics. Supervised and unsupervised learning algorithms play a vital role in identifying patterns, classifying compounds, and making predictions in drug discovery. They enable the exploration of vast chemical space, aiding in identifying potential drug candidates and target identification. Big Data and omics approaches have transformed drug discovery by integrating large-scale biological datasets, such as genomics, proteomics, and metabolomics. These approaches enable researchers to comprehensively understand disease biology, identify potential drug targets, and optimize drug design. Quantum mechanics-based approaches have opened up new avenues for drug discovery by providing a deeper understanding of molecular structures, interactions, and reactions. Despite challenges like computational resource requirements and scalability, these approaches offer improved accuracy and insights into drug design and optimization. The advancement of quantum computing holds promises for further enhancing computational modelling in drug discovery.

While computational approaches have made significant strides, challenges remain. Enhancing computational models' accuracy, efficiency, and validation is crucial to ensure reliable predictions. Addressing data availability, quality, and standardization issues will contribute to more robust and comprehensive analyses. Collaboration, data sharing, and the integration of multi-modal data will foster innovation and drive progress in the field. The computational approaches have transformed drug discovery, enabling faster, more efficient, and cost-effective identification and optimization of potential drug candidates. The integration of machine learning, artificial intelligence, quantum mechanics, big data, and omics approaches has paved the way for a new era of drug discovery. As researchers continue to address challenges and leverage emerging technologies, computational approaches will play an increasingly pivotal role in accelerating the discovery and development of safe and effective drugs, ultimately benefiting patients and advancing healthcare.

Compliance with ethical standards

Acknowledgments

We have not received any external funding for the research underlying this review work.

Disclosure of conflict of interest

All the authors disclose no conflicts of interest/competing interests.

References

[1] Lin X, Li X, Lin X. A review on applications of computational methods in drug screening and design. Molecules. 2020 Mar 18;25(6):1375.

[2] Bannigan P, Aldeghi M, Bao Z, Häse F, Aspuru-Guzik A, Allen C. Machine learning directed drug formulation development. Advanced Drug Delivery Reviews. 2021 Aug 1;175:113806.

[3] Hassan M, Awan FM, Naz A, deAndrés-Galiana EJ, Alvarez O, Cernea A, Fernández- Brillet L, Fernández-Martínez JL, Kloczkowski A. Innovations in genomics and big data analytics for personalized medicine and health care: A review. International journal of molecular sciences. 2022 Apr 22;23(9):4645.

[4] Blay V, Tolani B, Ho SP, Arkin MR. High-throughput screening: today's biochemical and cell-based approaches. Drug Discovery Today. 2020 Oct 1;25(10):1807-21.

[5] Du Y, Li X, Niu Q, Mo X, Qui M, Ma T, Kuo CJ, Fu H. Development of a miniaturized 3D organoid culture platform for ultra-high-throughput screening. Journal of Molecular Cell Biology. 2020 Aug;12(8):630-43.

[6] Li H, Hsieh K, Wong PK, Mach KE, Liao JC, Wang TH. Single-cell pathogen diagnostics for combating antibiotic resistance. Nature Reviews Methods Primers. 2023 Feb 2;3(1):6.

[7] Simon RP, Winter M, Kleiner C, Ries R, Schnapp G, Heimann A, Li J, Zuvela-Jelaska L, Bretschneider T, Luippold AH, Reindl W. MALDI-TOF mass spectrometry-based high- throughput screening for inhibitors of the cytosolic DNA sensor cGAS. SLAS DISCOVERY: Advancing the Science of Drug Discovery. 2020 Apr;25(4):372-83.

[8] Blay V, Tolani B, Ho SP, Arkin MR. High-throughput screening: today's biochemical and cell-based approaches. Drug Discovery Today. 2020 Oct 1;25(10):1807-21.

[9] Payne EM, Holland-Moritz DA, Sun S, Kennedy RT. High-throughput screening by droplet microfluidics: Perspective into key challenges and future prospects. Lab on a Chip. 2020;20(13):2247-62.

[10] Agamah FE, Mazandu GK, Hassan R, Bope CD, Thomford NE, Ghansah A, Chimusa ER. Computational/in silico methods in drug target and lead prediction. Briefings in bioinformatics. 2020 Sep;21(5):1663-75.

[11] Schauperl M, Denny RA. AI-Based protein structure prediction in drug discovery: Impacts and challenges. Journal of Chemical Information and Modeling. 2022 Jun 21;62(13):3142- 56.

[12] Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: advances and opportunities. Nature reviews Drug discovery. 2021 Mar;20(3):200-16.

[13] Chopra B, Dhingra AK. Natural products: A lead for drug discovery and development. Phytotherapy Research. 2021 Sep;35(9):4660-702.

[14] Abdel-Razek AS, El-Naggar ME, Allam A, Morsy OM, Othman SI. Microbial natural products in drug discovery. Processes. 2020 Apr 16;8(4):470.

[15] Prihoda D, Maritz JM, Klempir O, Dzamba D, Woelk CH, Hazuda DJ, Bitton DA, Hannigan GD. The application potential of machine learning and genomics for understanding natural product diversity, chemistry, and therapeutic translatability. Natural Product Reports. 2021;38(6):1100-8.

[16] Zhong Z, He B, Li J, Li YX. Challenges and advances in genome mining of ribosomally synthesized and post-translationally modified peptides (RiPPs). Synthetic and Systems Biotechnology. 2020 Sep 1;5(3):155-72.

[17] Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nature reviews Drug discovery. 2021 Apr;20(4):309-25.

[18] Marshall LJ, Bailey J, Cassotta M, Herrmann K, Pistollato F. Poor translatability of biomedical research using animals—A narrative review. Alternatives to Laboratory Animals. 2023 Mar;51(2):102-35.

[19] Deore AB, Dhumane JR, Wagh R, Sonawane R. The stages of drug discovery and development process. Asian Journal of Pharmaceutical Research and Development. 2019 Dec 15;7(6):62-7.

[20] Bender A, Cortés-Ciriano I. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: ways to make an impact, and why we are not there yet. Drug Discovery Today. 2021 Feb 1;26(2):511-24.

[21] Zhou LM, Qu RY, Yang GF. An overview of spirooxindole as a promising scaffold for novel drug discovery. Expert Opinion on Drug Discovery. 2020 May 3;15(5):603-25.

[22] Holzinger A, Keiblinger K, Holub P, Zatloukal K, Müller H. AI for life: Trends in artificial intelligence for biotechnology. New Biotechnology. 2023 May 25;74:16-24.

[23] Singh AV, Ansari MH, Rosenkranz D, Maharjan RS, Kriegel FL, Gandhi K, Kanase A, Singh R, Laux P, Luch A. Artificial intelligence and machine learning in computational nanotoxicology: unlocking and empowering nanomedicine. Advanced Healthcare Materials. 2020 Sep;9(17):1901862.

[24] Biswas N, Chakrabarti S. Artificial intelligence (AI)-based systems biology approaches in multi-omics data analysis of cancer. Frontiers in Oncology. 2020 Oct 14;10:588221.

[25] Choudhury C, Murugan NA, Priyakumar UD. Structure-based drug repurposing: Traditional and advanced AI/ML-aided methods. Drug Discovery Today. 2022 Mar 14.

[26] Martinelli DD. Generative machine learning for de novo drug discovery: A systematic review. Computers in Biology and Medicine. 2022 Jun 1;145:105403.

[27] Zhang B, Li H, Yu K, Jin Z. Molecular docking-based computational platform for high- throughput virtual screening. CCF Transactions on High Performance Computing. 2022 Jan 13:1-2.

[28] Perez Santin E, Rodríguez Solana R, González García M, García Suárez MD, Blanco Díaz GD, Cima Cabal MD, Moreno Rojas JM, Lopez Sanchez JI. Toxicity prediction based on artificial intelligence: A multidisciplinary overview. Wiley Interdisciplinary Reviews: Computational Molecular Science. 2021 Sep;11(5):e1516.

[29] Kolluri S, Lin J, Liu R, Zhang Y, Zhang W. Machine learning and artificial intelligence in pharmaceutical research and development: a review. The AAPS Journal. 2022 Feb;24:1-0.

[30] Zhou JB, Tang D, He L, Lin S, Lei JH, Sun H, Xu X, Deng CX. Machine learning model for anti-cancer drug combinations: Analysis, prediction, and validation. Pharmacological Research. 2023 Jun 19:106830.

[31] Fan K, Cheng L, Li L. Artificial intelligence and machine learning methods in predicting anti-cancer drug combination effects. Briefings in bioinformatics. 2021 Nov;22(6):bbab271.

[32] Murugan NA, Priya GR, Sastry GN, Markidis S. Artificial intelligence in virtual screening: Models versus experiments. Drug Discovery Today. 2022 May 18.

[33] Šícho M, Luukkonen S, van den Maagdenberg HW, Schoenmaker L, Béquignon OJ, van Westen GJ. DrugEx: deep learning models and tools for exploration of drug-like chemical space. Journal of Chemical Information and Modeling. 2023 Mar 17.

[34] Saldívar-González FI, Medina-Franco JL. Approaches for enhancing the analysis of chemical space for drug discovery. Expert Opinion on Drug Discovery. 2022 Jul 3;17(7):789-98.

[35] Singh AV, Varma M, Laux P, Choudhary S, Datusalia AK, Gupta N, Luch A, Gandhi A, Kulkarni P, Nath B. Artificial intelligence and machine learning disciplines with the potential to improve the nanotoxicology and nanomedicine fields: a comprehensive review. Archives of Toxicology. 2023 Apr;97(4):963-79.

[36] Durán-Iturbide NA, Díaz-Eufracio BI, Medina-Franco JL. In silico ADME/Tox profiling of natural products: A focus on BIOFACQUIM. ACS omega. 2020 Jun 25;5(26):16076- 84.

[37] de Jong J, Cutcutache I, Page M, Elmoufti S, Dilley C, Fröhlich H, Armstrong M. Towards realizing the vision of precision medicine: AI based prediction of clinical drug response. Brain. 2021 Jun;144(6):1738-50.

[38] Sebastiani M, Vacchi C, Manfredi A, Cassone G. Personalized Medicine and Machine Learning: A Roadmap for the Future. Journal of Clinical Medicine. 2022 Jul 15;11(14):4110.

[39] Wu L, Wen Y, Leng D, Zhang Q, Dai C, Wang Z, Liu Z, Yan B, Zhang Y, Wang J, He S. Machine learning methods, databases and tools for drug combination prediction. Briefings in bioinformatics. 2022 Jan;23(1):bbab355.

[40] Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Molecular diversity. 2021 Aug;25:1315-60.

[41] Priya S, Tripathi G, Singh DB, Jain P, Kumar A. Machine learning approaches and their applications in drug discovery and design. Chemical Biology & Drug Design. 2022 Jul;100(1):136-53.

[42] Lee JW, Maria-Solano MA, Vu TN, Yoon S, Choi S. Big data and artificial intelligence (AI) methodologies for computer-aided drug design (CADD). Biochemical Society Transactions. 2022 Feb 28;50(1):241-52.

[43] Patel L, Shukla T, Huang X, Ussery DW, Wang S. Machine learning methods in drug discovery. Molecules. 2020 Nov 12;25(22):5277.

[44] Hu S, Zhang C, Chen P, Gu P, Zhang J, Wang B. Predicting drug-target interactions from drug structure and protein sequence using novel convolutional neural networks. BMC bioinformatics. 2019 Dec;20:1-2.

[45] Zhang Y, Qiu Y, Cui Y, Liu S, Zhang W. Predicting drug-drug interactions using multi- modal deep auto-encoders based network embedding and positive-unlabeled learning. Methods. 2020 Jul 1;179:37-46.

[46] Pei X, Zuo K, Li Y, Pang Z. A Review of the Application of Multi-modal Deep Learning in Medicine: Bibliometrics and Future Directions. International Journal of Computational Intelligence Systems. 2023 Mar 29;16(1):44.

[47] Tao D, Yang P, Feng H. Utilization of text mining as a big data analysis tool for food science and nutrition. Comprehensive reviews in food science and food safety. 2020 Mar;19(2):875-94.

[48] Veenstra TD. Omics in systems biology: current progress and future outlook. Proteomics. 2021 Feb;21(3-4):2000235.

[49] Ma J, Deng Y, Zhang M, Yu J. The role of multi-omics in the diagnosis of COVID-19 and the prediction of new therapeutic targets. Virulence. 2022 Dec 31;13(1):1101-10.

[50] Kwoji ID, Aiyegoro OA, Okpeku M, Adeleke MA. 'Multi-omics' data integration: applications in probiotics studies. npj Science of Food. 2023 Jun 5;7(1):25.

[51] Sookoian S, Pirola CJ. Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology. Clinical and molecular hepatology. 2020 Oct;26(4):461.

[52] Enoma DO, Bishung J, Abiodun T, Ogunlana O, Osamor VC. Machine learning approaches to genome-wide association studies. Journal of King Saud University-Science. 2022 Jan 22:101847.

[53] Zhou Y, Tremmel R, Schaeffeler E, Schwab M, Lauschke VM. Challenges and opportunities associated with rare-variant pharmacogenomics. Trends in Pharmacological Sciences. 2022 Aug 22.

[54] Morganti S, Tarantino P, Ferraro E, D'Amico P, Duso BA, Curigliano G. Next Generation Sequencing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in cancer. Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics. 2019:9-30.

[55] Xiao H, Sun F, Suttapitugsakul S, Wu R. Global and site-specific analysis of protein glycosylation in complex biological systems with Mass Spectrometry. Mass spectrometry reviews. 2019 Aug;38(4-5):356-79.

[56] Paananen J, Fortino V. An omics perspective on drug target discovery platforms. Briefings in bioinformatics. 2020 Nov;21(6):1937-53.

[57] Qiu S, Cai Y, Yao H, Lin C, Xie Y, Tang S, Zhang A. Small molecule metabolites: discovery of biomarkers and therapeutic targets. Signal Transduction and Targeted Therapy. 2023 Mar 20;8(1):132.

[58] Srivastava S. Emerging insights into the metabolic alterations in aging using metabolomics. Metabolites. 2019 Dec 13;9(12):301.

[59] Banimfreg BH, Alshraideh H, Shamayleh A, Guella A, Semreen MH, Al Bataineh MT, Soares NC. Untargeted metabolomic plasma profiling of emirati dialysis patients with diabetes versus non-diabetic: A pilot study. Biomolecules. 2022 Jul 8;12(7):962.

[60] Tounta V, Liu Y, Cheyne A, Larrouy-Maumus G. Metabolomics in infectious diseases and drug discovery. Molecular Omics. 2021;17(3):376-93.

[61] Seney ML, Glausier J, Sibille E. Large-scale transcriptomics studies provide insight into sex differences in depression. Biological psychiatry. 2022 Jan 1;91(1):14-24.

[62] Chew G, Petretto E. Transcriptional networks of microglia in Alzheimer's disease and insights into pathogenesis. Genes. 2019 Oct 12;10(10):798.

[63] Wu YL, Lin ZJ, Li CC, Lin X, Shan SK, Guo B, Zheng MH, Li F, Yuan LQ, Li ZH. Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study. Signal Transduction and Targeted Therapy. 2023 Mar 2;8(1):98.

[64] Villanueva L, Álvarez-Errico D, Esteller M. The contribution of epigenetics to cancer immunotherapy. Trends in immunology. 2020 Aug 1;41(8):676-91.

[65] Singh DB. The impact of pharmacogenomics in personalized medicine. Current Applications of Pharmaceutical Biotechnology. 2020:369-94.

[66] Sadee W, Wang D, Hartmann K, Toland AE. Pharmacogenomics: Driving personalized medicine. Pharmacological Reviews. 2023 Jul 1;75(4):789-814.

[67] Harbola A, Negi D, Manchanda M, Kesharwani RK. Bioinformatics and biological data mining. InBioinformatics 2022 Jan 1 (pp. 457-471). Academic Press.

[68] Saberi-Karimian M, Khorasanchi Z, Ghazizadeh H, Tayefi M, Saffar S, Ferns GA, Ghayour-Mobarhan M. Potential value and impact of data mining and machine learning in clinical diagnostics. Critical reviews in clinical laboratory sciences. 2021 May 19;58(4):275-96.

[69] Wang L, Ding J, Pan L, Cao D, Jiang H, Ding X. Artificial intelligence facilitates drug design in the big data era. Chemometrics and Intelligent Laboratory Systems. 2019 Nov 15;194:103850.

[70] Liu B, He H, Luo H, Zhang T, Jiang J. Artificial intelligence and big data facilitated targeted drug discovery. Stroke and Vascular Neurology. 2019 Dec 1;4(4).

[71] Patel V, Shah M. Artificial intelligence and machine learning in drug discovery and development. Intelligent Medicine. 2022 Aug 1;2(3):134-40.

[72] Gorgulla C, Jayaraj A, Fackeldey K, Arthanari H. Emerging frontiers in virtual drug discovery: From quantum mechanical methods to deep learning approaches. Current Opinion in Chemical Biology. 2022 Aug 1;69:102156.

[73] Bassani D, Moro S. Past, Present, and Future Perspectives on Computer-Aided Drug Design Methodologies. Molecules. 2023 May 5;28(9):3906.

[74] Gorgulla C, Jayaraj A, Fackeldey K, Arthanari H. Emerging frontiers in virtual drug discovery: From quantum mechanical methods to deep learning approaches. Current Opinion in Chemical Biology. 2022 Aug 1;69:102156.

[75] Morawietz T, Artrith N. Machine learning-accelerated quantum mechanics-based atomistic simulations for industrial applications. Journal of Computer-Aided Molecular Design. 2021 Apr;35(4):557-86.

[76] Chan HS, Shan H, Dahoun T, Vogel H, Yuan S. Advancing drug discovery via artificial intelligence. Trends in pharmacological sciences. 2019 Aug 1;40(8):592-604.

[77] Naserifar S, Oppenheim JJ, Yang H, Zhou T, Zybin S, Rizk M, Goddard WA. Accurate non-bonded potentials based on periodic quantum mechanics calculations for use in molecular simulations of materials and systems. The Journal of Chemical Physics. 2019 Oct 21;151(15).

[78] Bodenschatz CJ, Zhang X, Xie T, Arvay J, Sarupria S, Getman RB. Multiscale sampling of a heterogeneous water/metal catalyst interface using density functional theory and force- field molecular dynamics. JoVE (Journal of Visualized Experiments). 2019 Apr 12(146):e59284.

[79] Kairys V, Baranauskiene L, Kazlauskiene M, Matulis D, Kazlauskas E. Binding affinity in drug design: experimental and computational techniques. Expert opinion on drug discovery. 2019 Aug 3;14(8):755-68.

[80] Funes-Ardoiz I, Schoenebeck F. Established and emerging computational tools to study homogeneous catalysis—From quantum mechanics to machine learning. Chem. 2020 Aug 6;6(8):1904-13.

[81] Keith JA, Vassilev-Galindo V, Cheng B, Chmiela S, Gastegger M, Müller KR, Tkatchenko A. Combining machine learning and computational chemistry for predictive insights into chemical systems. Chemical reviews. 2021 Jul 7;121(16):9816-72.

[82] Casalini T. Not only in silico drug discovery: Molecular modeling towards in silico drug delivery formulations. Journal of Controlled Release. 2021 Apr 10;332:390-417.

[83] Salo-Ahen OM, Alanko I, Bhadane R, Bonvin AM, Honorato RV, Hossain S, Juffer AH, Kabedev A, Lahtela-Kakkonen M, Larsen AS, Lescrinier E. Molecular dynamics simulations in drug discovery and pharmaceutical development. Processes. 2020 Dec 30;9(1):71.

[84] Sadybekov AV, Katritch V. Computational approaches streamlining drug discovery. Nature. 2023 Apr 27;616(7958):673-85.